![Gavin Xia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gavin Xia
No más puestos en curso
Fortuna: 179 M $ al 31/07/2026
Perfil
Dr. Gavin Xia is a Chief Executive Officer at Alebund Pharmaceuticals (Jiangsu) Ltd., a Chief Executive Officer at Shanghai Alebund Pharmaceutical Technology Co., Ltd. and a Venture Partner at LAV Management Co., Ltd. Dr. Xia was previously employed as a Non-Executive Director by Abbisko Cayman Ltd. and a Non-Executive Director by Abbisko Therapeutics Co., Ltd. He also served on the board at Shanghai Kun Yuan Biotechnology Co. Ltd. and Beijing Jiakesi New Drug Development Co. Ltd. He received his undergraduate degree from Peking University and a doctorate degree from The University of Chicago.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
11,33 % | 29/06/2026 | 32.069.014 ( 11,33 % ) | 111 M $ | 31/07/2026 |
8,54 % | 29/07/2026 | 19.401.461 ( 8,54 % ) | 67 M $ | 31/07/2026 |
Cargos activos de Gavin Xia
| Empresas | Cargo | Inicio |
|---|---|---|
LAV Management Co., Ltd.
 LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Inversor de Capital Privado | - |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
 Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Director Ejecutivo | - |
Antiguos cargos conocidos de Gavin Xia.
| Empresas | Cargo | Fin |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Director/Miembro de la Junta | 19/06/2023 |
Shanghai Kun Yuan Biotechnology Co. Ltd. | Director/Miembro de la Junta | 01/02/2021 |
Beijing Jiakesi New Drug Development Co. Ltd.
 Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Director/Miembro de la Junta | - |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Director/Miembro de la Junta | - |
Formación de Gavin Xia.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
98
Relaciones de 1er grado
8
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 8 |
|---|---|
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Finance |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Health Technology |
Beijing Jiakesi New Drug Development Co. Ltd.
Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Health Technology |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Health Technology |
Abbisko Cayman Ltd.
 Abbisko Cayman Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule oncology therapies | Health Technology |
Shanghai Kun Yuan Biotechnology Co. Ltd. |
- Bolsa de valores
- Insiders
- Gavin Xia
